CLOs on the Move

Chugai Pharma

www.chugai-pharm.com

 
Chugai Pharma USA (CPUSA), a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd.(Chugai) located in Berkeley Heights NJ, is focused on early stage clinical research, mainly in the disease areas of oncology, renal disease, and bone and joint disease. CPUSA operates as part of Chugai`s Translational Clinical Research Division (TCRD), a global function with offices in Europe, Japan and the U.S. TCRD is dedicated to late pre-clinical and early clinical development of Chugai-originated pipeline products. TCRD aims to accelerate the proof-of-concept process by bringing translational research-powered medicines to global development stage and ultimately to market, as efficiently ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.chugai-pharm.com
  • 300 Connell Drive Suite 3100
    Berkeley Heights, NJ USA 07922
  • Phone: 908.516.1350

Executives

Name Title Contact Details

Similar Companies

SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc. is a Foster City, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

LifeTek Solutions

LifeTek Solutions is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Mary Crowley Medical Research

Mary Crowley Medical Research is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MHC Healthcare

MHC Healthcare is a network of health centers focused on serving the communities where our patients live. We promote and support accessible and affordable primary health care services for all individuals independent of socio-economic status, national o...

Artios Pharma

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.